Barclays’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-3,700
| Closed | -$379K | – | 7406 |
|
|
2019
Q2 | $379K | Buy |
3,700
+1,800
| +95% | +$194K | ﹤0.01% | 4573 |
|
|
2019
Q1 | $216K | Buy |
+1,900
| New | +$140K | ﹤0.01% | 4764 |
|
|
2018
Q4 | – | Sell |
-800
| Closed | -$44K | – | 7635 |
|
|
2018
Q3 | $44K | Buy |
+800
| New | +$54.7K | ﹤0.01% | 6159 |
|
|
2017
Q4 | – | Sell |
-5,000
| Closed | -$446K | – | 7251 |
|
|
2017
Q3 | $446K | Buy |
+5,000
| New | +$380K | ﹤0.01% | 3731 |
|
|
2017
Q1 | – | Sell |
-900
| Closed | -$45K | – | 7112 |
|
|
2016
Q4 | $45K | Buy |
+900
| New | +$48.2K | ﹤0.01% | 5238 |
|
|
2016
Q3 | – | Sell |
-165,000
| Closed | -$8.44M | – | 6906 |
|
|
2016
Q2 | $8.44M | Buy |
+165,000
| New | +$7.05M | 0.01% | 940 |
|
|
2016
Q1 | – | Sell |
-75,000
| Closed | -$3.38M | – | 6591 |
|
|
2015
Q4 | $3.38M | Buy |
75,000
+39,700
| +112% | +$2.08M | ﹤0.01% | 1599 |
|
|
2015
Q3 | $1.45M | Buy |
+35,300
| New | +$1.84M | ﹤0.01% | 2399 |
|
Barclays's ONCE Position: Q4 2019 in Review
Barclays sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 95,436 shares — an estimated $9.26M sold.
Barclays first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $14.9M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Barclays reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Barclays sold 95,436 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $9.26M.
- Barclays first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- Barclays's Spark Therapeutics, Inc. Common Stock position peaked at $14.9M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.